Flexion Therapeutics

Flexion Therapeutics advances drug candidates through clinical proof of concept and beyond, in partnership with pharmaceutical and biotechnology companies. By providing expertise and sharing risk, Flexion effectively expands the portfolios of its partners.

Ceragon Networks

Hive Blockchain Technologies Ltd

CarLotz

Seanergy Maritime Hlds

Surgalign Holdings, Inc.

trivago

These penny stocks have multiple growth drivers powering their businesses. That will push their prices to record heights in the future.

7 Penny Stocks with Millionaire-Maker Potential

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Flexion Therapeutics (FLXN).

Why Flexion Therapeutics (FLXN) Could Be an Impressive Growth Stock

The heavy selling pressure might have exhausted for Flexion Therapeutics (FLXN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 24.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Flexion Therapeutics (FLXN)

BURLINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the results from the randomized, open-label, Phase 2 pharmacokinetic (PK) trial of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) were published in Drugs in R&D . The study compared the plasma PK profile of ZILRETTA to immediate-release triamcinolone acetonide in crystalline suspension (TAcs) and assessed the safety and general tolerability of ZILRETTA in osteoarthritis (OA) of the shoulder.

Flexion Therapeutics Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA® in Shoulder Osteoarthritis (OA)

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q2 2021 Results - Earnings Call Transcript

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 12.00% and 0.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Flexion Therapeutics (FLXN) Reports Q2 Loss, Tops Revenue Estimates

BURLINGTON, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June 30, 2021.

Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights

BURLINGTON, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, August 4, 2021 at 4:30 p.m. ET.

Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Flexion Therapeutics continues to report steady revenue growth as ZILRETTA moves deeper into commercialization. Despite the ongoing pandemic, Flexion reported encouraging Q1 earnings.

Flexion Therapeutics: Sector Sell-Off Provides Opportunity To Reload At A Discount

BURLINGTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors. Mr. Koppikar will serve as the chair of Flexion's audit committee.

Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors

Checkpoint Therapeutics

Equillium Inc

ReShape Lifesciences

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

4 Biotech and Life Sciences Stocks Trading Under $10 With Gigantic Upside Potential

BURLINGTON, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2021 Raymond James Human Health Innovation Conference. The virtual fireside chat is scheduled to begin at 3:20 p.m. ET on Monday, June 21, 2021.

Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference

BURLINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO), effective July 1, 2021.

Flexion Therapeutics Announces Appointment of William T. Andrews, M.D.

BURLINGTON, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference. The virtual fireside chat is scheduled to begin at 3:50 p.m. ET on Tuesday, June 8, 2021.

Flexion Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference

BURLINGTON, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets 2021 Virtual Global Healthcare Conference. The virtual fireside chat is scheduled to begin at 1:55 p.m. ET on Wednesday, May 19, 2021.

Flexion Therapeutics to Present at the RBC Capital Markets 2021 Virtual Global Healthcare Conference

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q1 2021 Results - Earnings Call Transcript

Shares of Flexion Therapeutics (NASDAQ:FLXN) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 40.00% year over year to ($0.57), which missed the estimate of ($0.52).

Flexion Therapeutics: Q1 Earnings Insights

BURLINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended March 31, 2021.

Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates

On Wednesday, May 12, Flexion Therapeutics (NASDAQ:FLXN) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

Earnings Preview: Flexion Therapeutics

BURLINGTON, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, May 12, 2021.

Flexion Therapeutics to Report First-Quarter 2021 Financial Results on May 12, 2021

Last month, management guided Zilretta revenue to grow 50% to $120-130 million. Huge runway with under 5% market penetration into osteoarthritis knee pain indication. Despite growing revenue nearly 20% last year during the pandemic and guiding to 50% this year, shares trade at a 52-week low and under 4x revenue multiple.

It's Time To Buy Flexion Therapeutics As Revenue Is Expected To Grow

Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

BURLINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) will present preliminary data from a Phase 1 single ascending dose (SAD) trial of FX201 at the 2021 American Society of Gene & Cell Therapy (ASGCT) annual meeting taking place virtually May 11-14, 2021.

Flexion Therapeutics Announces Presentation of Preliminary FX201 Clinical Data at the Upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Alexion Pharma

Activision Blizzard

Baker Hughes Co

BioMarin Pharmaceutical

Esperion Therapeutics

Fate Therapeutics

Reata Pharmaceuticals

With the trading day about halfway over, each of the major averages had notched a solid gain and was holding just below its respective all-time high.

News for Flexion Therapeutics Stock (FLXN)